Keywords: ASCO, GlaxoSmithKline, Pazopanib, Novartis, INC424, Glivec, Bristol-Myers, Otsuka, Sprycel, Ruxolitinib

ASCO highlights include GSK’s pazopanib, Novartis’ INC424 and Glivec, B-MS/Otsuka’s Sprycel

Article | 06 June 2011

Print This

This year's annual meeting of the American Society for Clinical Oncology (ASCO), being held in Chicago, saw a plethora of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in